IllnessHypogonadism, hypogonadotropic; differential diagnosis
Summary
Comprehensive differential diagnostic panel for Hypogonadism, hypogonadotropic comprising 14 or altogether 62 curated genes according to the clinical signs
100,2 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
ANOS1 | 2043 | NM_000216.4 | XLR | |
CHD7 | 8994 | NM_017780.4 | AD | |
FEZF1 | 1428 | NM_001024613.4 | AR | |
FGF8 | 735 | NM_033163.5 | AD, AR | |
FGFR1 | 2469 | NM_023110.3 | AR | |
GNRH1 | 291 | NM_000825.3 | AR | |
GNRHR | 987 | NM_000406.3 | AR | |
IL17RD | 2220 | NM_017563.5 | AR | |
KISS1R | 1197 | NM_032551.5 | AR | |
NSMF | 1587 | NM_015537.5 | AR | |
PROK2 | 390 | NM_001126128.2 | AR, Oligo, AD | |
PROKR2 | 1155 | NM_144773.4 | AR | |
TAC3 | 366 | NM_013251.4 | AR | |
TACR3 | 1398 | NM_001059.3 | AR | |
CLPP | 834 | NM_006012.4 | AR | |
CPE | 1431 | NM_001873.4 | AR | |
CUL4B | 2742 | NM_003588.4 | XLR | |
DCAF17 | 1563 | NM_025000.4 | AR | |
DUSP6 | 1146 | NM_001946.4 | AD | |
FGF17 | 651 | NM_003867.4 | AD | |
FLRT3 | 1950 | NM_198391.3 | AD | |
FSHB | 390 | NM_000510.4 | AR | |
GLI2 | 4761 | NM_005270.5 | AD | |
HAMP | 255 | NM_021175.4 | AR | |
HESX1 | 558 | NM_003865.3 | AD, AR | |
HFE | 1047 | NM_000410.4 | AR | |
HS6ST1 | 1236 | NM_004807.3 | AD | |
KISS1 | 417 | NM_002256.4 | AR | |
KLB | 3135 | NM_175737.4 | AD | |
LEP | 504 | NM_000230.3 | AR | |
LEPR | 3498 | NM_002303.6 | AR | |
LHB | 426 | NM_000894.3 | AR | |
LHX3 | 1209 | NM_014564.5 | AR | |
LHX4 | 1173 | NM_033343.4 | AD | |
NR0B1 | 1413 | NM_000475.5 | XLR | |
PCSK1 | 2262 | NM_000439.5 | AR | |
PNPLA6 | 3984 | NM_006702.5 | AR | |
POLR3A | 4173 | NM_007055.4 | AR | |
POLR3B | 3402 | NM_018082.6 | AR | |
POU1F1 | 876 | NM_000306.4 | AR, AD | |
PROP1 | 681 | NM_006261.5 | AR | |
RAB3GAP1 | 2946 | NM_012233.3 | AR | |
RAB3GAP2 | 4182 | NM_012414.4 | AR | |
RNF216 | 2772 | NM_207111.4 | AR | |
SEMA3A | 2316 | NM_006080.3 | AD | |
SLC29A3 | 1428 | NM_018344.6 | AR | |
SLC40A1 | 1716 | NM_014585.6 | AD | |
SOX10 | 1401 | NM_006941.4 | AD | |
SOX2 | 954 | NM_003106.4 | AD | |
SPRY4 | 969 | NM_030964.5 | AD | |
STUB1 | 912 | NM_005861.4 | AD, AR | |
TCF12 | 2121 | NM_207036.2 | AD | |
TFR2 | 2406 | NM_003227.4 | AR | |
TUBB3 | 1353 | NM_006086.4 | AR | |
WDR11 | 3675 | NM_018117.12 | AD |
Informations about the disease
Hypogonadotropic hypogonadism (HH) is either due to low concentrations of sexual steroids (oestrogen, progesterone) or gonadotropins (FSH, LH) with hypothalamic or pituitary causes. The majority of cases is diagnosed in men; women usually have primary amenorrhoea, which is often not genetic. HH can occur congenitally or later, and is usually diagnosed definitively at the age of 18 years. The detection rate is significantly higher in congenital HH (35-60%) than in late puberty as an expression of later manifested forms of HH that cannot be clinically distinguished. Statements on penetrance rates and expressivity must be made on the basis of genes or mutations. An inconspicuous genetic finding certainly does not mean that the suspected clinical diagnosis is excluded.
Reference: https://www.nature.com/articles/nrendo.2015.112
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520594/
- Allelic: CHARGE syndrome (CHD7)
- Allelic: Encephalocraniocutaneous lipomatosis, somatic mosaic (FGFR1)
- Allelic: Encephalocraniocutaneous lipomatosis; Hartsfield syndrome; Jackson-Weiss syndrome (FGFR1)
- Allelic: Fascioscapulohumeral muscular dystrophy 2, digenic (SMCHD1)
- Allelic: Hartsfield syndrome (FGFR1)
- Allelic: Holoprosencephaly 9 (GLI2)
- Allelic: Jackson-Weiss syndrome (FGFR1)
- Allelic: Laurence-Moon syndrome (PNPLA6)
- Allelic: Microphthalmia, syndromic 3 (SOX2)
- Allelic: Obesity, susceptibility to, BMIQ12 (PCSK1)
- Allelic: Obesity, susceptibility to, BMIQ14 (FTO)
- Allelic: Oliver-McFarlane syndrome (PNPLA6)
- Allelic: Osteoglophonic dysplasia (FGFR1)
- Allelic: Osteoglophonic dysplasia; Pfeiffer syndrome; Trigonocephaly 1 (FGFR1)
- Allelic: PCWH syndrome (SOX10)
- Allelic: Pfeiffer syndrome (FGFR1)
- Allelic: Precocious puberty, central, 1 (KISS1R)
- Allelic: Septooptic dysplasia (HESX1)
- Allelic: Spastic paraplegia 39, AR (PNPLA6)
- Allelic: Treacher Collins syndrome 3 (POLRR1C)
- Allelic: Trigonocephaly 1 (FGFR1)
- Allelic: Wiedemann-Rautenstrauch syndrome (POLR3A)
- 46XY sex reversal 2, dosage-sensitive (NR0B1)
- Adrenal hypoplasia, congenital (NR0B1)
- Allelic: Blood group, John-Milton-Hagen system (SEMA7A)
- Allelic: Luteinizing hormone resistance, female (LHCGR)
- Allelic: Precocious puberty, male (LHCGR)
- Alopecia, neurologic defects + endocrinopathy syndrome (RBM28)
- Bardet-Biedl syndrome genes (Rp, obesity, kidney dysfunction, hypogonadism...)
- Bosma arhinia microphthalmia syndrome (SMCHD1)
- Boucher-Neuhauser syndrome (PNPLA6)
- CHARGE syndrome (SEMA3E)
- Cerebellar ataxia + hypogonadotropic hypogonadism (RNF216)
- Congenital hypogonadotropic hypogonadism (KLB)
- Congenital hypogonadotropic hypogonadism [MONDO:0015770] (CCDC141)
- Craniosynostosis 3 (TCF12)
- Culler-Jones syndrome (GLI2)
- Fibrosis of extraocular muscles, congenital, 3A (TUBB3)
- Growth hormone deficiency with pituitary anomalies (HESX1)
- Growth retardation, developmental delay, facial dysmorphism (FTO)
- Hemochromatosis (HFE)
- Hemochromatosis, type 2B (HAMP)
- Hemochromatosis, type 3 (TFR2)
- Hemochromatosis, type 4 (SLC40A1)
- Histiocytosis-lymphadenopathy plus syndrome (SLC29A3)
- Hypogonadotropic hypogonadism 1 with/-out anosmia; Kallmann syndrome 1 (ANOS1)
- Hypogonadotropic hypogonadism 10 with/-out anosmia (TAC3)
- Hypogonadotropic hypogonadism 11 with/-out anosmia (TACR3)
- Hypogonadotropic hypogonadism 12 with/-out anosmia (GNRH1)
- Hypogonadotropic hypogonadism 13 with/-out anosmia (KISS1)
- Hypogonadotropic hypogonadism 14 with/-out anosmia (WDR11)
- Hypogonadotropic hypogonadism 15 with/-out anosmia (HS6ST1)
- Hypogonadotropic hypogonadism 16 with/-out anosmia (SEMA3A)
- Hypogonadotropic hypogonadism 17 with/-out anosmia (SPRY4)
- Hypogonadotropic hypogonadism 18 with/-out anosmia (IL17RD)
- Hypogonadotropic hypogonadism 19 with/_out anosmia (DUSP6)
- Hypogonadotropic hypogonadism 2 with/-out anosmia (FGFR1)
- Hypogonadotropic hypogonadism 20 with/-out anosmia (FGF17)
- Hypogonadotropic hypogonadism 21 with anosmia (FLRT3)
- Hypogonadotropic hypogonadism 22, with/-out anosmia (FEZF1)
- Hypogonadotropic hypogonadism 23 with/-out anosmia (LHB)
- Hypogonadotropic hypogonadism 24 without anosmia (FSHB)
- Hypogonadotropic hypogonadism 25 with anosmia (NDNF)
- Hypogonadotropic hypogonadism 3 with/-out anosmia (PROKR2)
- Hypogonadotropic hypogonadism 4 with/-out anosmia (PROK2)
- Hypogonadotropic hypogonadism 5 with/-out anosmia (CHD7)
- Hypogonadotropic hypogonadism 6 with/-out anosmia (FGF8)
- Hypogonadotropic hypogonadism 7 without anosmia (GNRHR)
- Hypogonadotropic hypogonadism 8 with/-out anosmia (KISS1R)
- Hypogonadotropic hypogonadism 9 with/_out anosmia (NSMF)
- Hypogonadotropic hypogonadism [MONDO:0018555] (SEMA3F)
- Hypogonadotropic hypogonadism without anosmia; normosmic IHH [panelapp] (CCDC141)
- Hypogonadotropic hypogonadism, delayed puberty, primary ovary insufficiency [panelapp] (IGSF10)
- Intellectual developmental disorder + hypogonadotropic hypogonadism (CPE)
- Isolated GnRH deficiency [genereviews] (AXL)
- Isolated GnRH deficiency [genereviews] (SRA1)
- Leukodystrophy, hypomyelinating, 11 (POLR1C)
- Leukodystrophy, hypomyelinating, 7, with/-out oligodontia and/or hypogon. hypogonadism (POLR3A)
- Leukodystrophy, hypomyelinating, 8, with/-out oligodontia and/or hypogon. hypogonadism (POL3RB)
- Leydig cell hypoplasia with hypergonadotropic hypogonadism (LHCGR)
- Martsolf syndrome 1 (RAB3GAP2)
- Martsolf syndrome 2 (RAB3GAB1)
- Mental retardation, XL, syndromic 15 [Cabezas type] (CUL4B)
- Obesity with impaired prohormone processing (PCSK1)
- Obesity, morbid, due to leptin deficiency (LEP)
- Obesity, morbid, due to leptin receptor deficiency (LEPR)
- Optic nerve hypoplasia + abnormalities of the central nervous system (SOX2)
- PCWH syndrome (SOX10)
- Perrault syndrome 3 (CLPP)
- Pituitary hormone deficiency, combined, 1 (POUF1)
- Pituitary hormone deficiency, combined, 2 (PROP1)
- Pituitary hormone deficiency, combined, 3 (LHX3)
- Pituitary hormone deficiency, combined, 4 (LHX4)
- Pituitary hormone deficiency, combined, 5 (HESX1)
- Prader-Willi syndrome (NDN, SIM1, SNRPN)
- Spinocerebellar ataxia, AR 16 (STUB1)
- Waardenburg syndrome, type 2E, with/-out neurologic involvement (SOX10)
- Waardenburg syndrome, type 4C (SOX10)
- Warburg micro syndrome 1 (RAB3GAP1)
- Warburg micro syndrome 2 (RAB3GAP2)
- Woodhouse-Sakati syndrome (DCAF17)
- AD
- AR
- Oligo
- XLR
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.